Published in BMC Cell Biol on January 26, 2009
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem (2003) 3.65
TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J (2003) 2.55
Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J (2000) 2.29
Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem (2000) 2.11
A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem (1997) 1.99
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis (1992) 1.79
Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem (2000) 1.75
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene (1999) 1.46
Conformation and unfolding thermodynamics of epidermal growth factor and derivatives. Biochemistry (1976) 1.43
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem (1996) 1.36
The enzymatic degradation of heparin and heparitin sulfate. 3. Purification of a heparitinase and a heparinase from flavobacteria. J Biol Chem (1970) 1.34
Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry (2004) 1.21
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene (2007) 1.18
Heparanase protein and gene expression in bladder cancer. J Urol (2001) 1.13
Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol (2003) 1.11
Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery (2002) 1.10
Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res (2001) 1.10
Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem (2005) 1.02
Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci (1999) 1.00
Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol (2006) 2.87
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem (2005) 2.03
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res (2006) 1.85
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol (2011) 1.61
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.57
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J (2003) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood (2004) 1.35
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
Function of ERBB4 is determined by alternative splicing. Cell Cycle (2011) 1.26
Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem (2005) 1.24
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell (2006) 1.23
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Genome-wide identification of novel genes involved in early Th1 and Th2 cell differentiation. J Immunol (2007) 1.21
Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem (2004) 1.20
Fibroblast growth factors share binding sites in heparan sulphate. Biochem J (2005) 1.15
Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem (2008) 1.11
Endothelial cell-matrix interactions. Microsc Res Tech (2003) 1.09
Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia (2009) 1.09
The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood (2009) 1.08
PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood (2009) 1.08
Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell (2010) 1.07
The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood (2007) 1.05
Molecular identification of PAL-E, a widely used endothelial-cell marker. Blood (2005) 1.03
The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem J (2002) 1.02
IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation. J Immunol (2004) 0.99
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol (2009) 0.98
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol (2005) 0.95
Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp Cell Res (2008) 0.93
Potential of ErbB4 antibodies for cancer therapy. Future Oncol (2010) 0.93
Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res (2007) 0.92
Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b. J Biol Chem (2002) 0.91
Altered expression of syndecan-1 in prostate cancer. APMIS (2004) 0.91
ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet (2013) 0.90
Proteolytic processing of ErbB4 in breast cancer. PLoS One (2012) 0.90
Impact of polydextrose on the faecal microbiota: a double-blind, crossover, placebo-controlled feeding study in healthy human subjects. Br J Nutr (2011) 0.90
Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization. J Invest Dermatol (2007) 0.89
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res (2009) 0.89
Protein kinase A balances the growth factor-induced Ras/ERK signaling. FEBS Lett (2002) 0.89
A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol (2003) 0.89
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem (2012) 0.89
ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol (2004) 0.88
Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation. EJNMMI Res (2011) 0.87
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem (2012) 0.87
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol (2013) 0.86
Effect of brefeldin A on heparan sulphate biosynthesis in Madin-Darby canine kidney cells. Biochem J (2002) 0.83
Betaine supplementation causes increase in carnitine metabolites in the muscle and liver of mice fed a high-fat diet as studied by nontargeted LC-MS metabolomics approach. Mol Nutr Food Res (2013) 0.82
Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res (2009) 0.81
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs (2010) 0.80
Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem (2003) 0.80
Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. Exp Cell Res (2010) 0.79
Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol Med (2007) 0.79
ErbB targeted drugs and angiogenesis. Curr Vasc Pharmacol (2010) 0.79
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost (2007) 0.78
Cooperation of protein kinase A and Ras/ERK signaling pathways is required for AP-1-mediated activation of fibroblast growth factor-inducible response element (FiRE). J Biol Chem (2002) 0.77
Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein. Biochem Biophys Res Commun (2002) 0.77
ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis. Mol Endocrinol (2014) 0.76
ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq (2008) 0.76
Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. PLoS One (2012) 0.75
Bifidobacterium animalis ssp. lactis 420 Protects against Indomethacin-Induced Gastric Permeability in Rats. Gastroenterol Res Pract (2012) 0.75
Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example. Genet Test Mol Biomarkers (2012) 0.75
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiother Oncol (2007) 0.75
Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells. Growth Factors (2006) 0.75